April 2, 2018 08:21 AM EDT
R&D

Bounc­ing back, Med­i­ci­No­va makes big gains af­ter tout­ing triglyc­eride da­ta from a tiny study

John Carroll

Editor & Founder

Shares of Med­i­ci­No­va rock­et­ed up more than 30% this morn­ing af­ter the biotech $MNOV tout­ed the ear­ly end of a small Phase IIa NASH …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

Is there still hope for Sum­mit's can­cer drug buried in the da­ta?

MIT sci­en­tists’ AI mod­el one-ups Al­phaFold 3, takes on ‘fun­da­men­tal is­sue’ in drug R&D

EMA con­sid­ers se­ri­ous eye con­di­tion a ‘very rare’ side ef­fect of semaglu­tide 

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

At a cross­roads, biotechs are pass­ing on re­verse merg­ers in 2025

sponsored

Cy­ti­va and Eu­rek­aBio form strate­gic part­ner­ship to ad­vance lentivi­ral vec­tor man­u­fac­tur­ing for cell and gene ther­a­py ...

A service from the Financial Times